Piper Sandler raised the firm’s price target on GeneDx (WGS) to $120 from $110 following quarterly results. The firm keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx Reports Record Revenue and Growth in Q2 2025
- GeneDx price target raised to $125 from $100 at BTIG
- GeneDx Holdings Reports Strong Q2 2025 Results
- GeneDx Holdings: Strong Growth Prospects and Expansion Opportunities Justify Buy Rating
- GeneDx raises 2025 revenue view to $400M-$415M from $360M-$375M